keyword
MENU ▼
Read by QxMD icon Read
search

Nonmotor parkinson's disease

keyword
https://www.readbyqxmd.com/read/27913696/insights-gleaned-by-measuring-patients-stated-goals-for-dbs-more-than-tremor
#1
Cynthia S Kubu, Scott E Cooper, Andre Machado, Thomas Frazier, Jerrold Vitek, Paul J Ford
OBJECTIVE: To report prospective repeated measures data detailing the perceived benefit of deep brain stimulation (DBS) on the most commonly cited symptom and activity goals identified by patients with Parkinson disease. METHODS: Fifty-two participants were recruited from a consecutive series. Participants completed a semi-structured interview soliciting their symptom and behavioral goals and corresponding visual analog scales measuring perceived symptom severity and limits to goal attainment...
December 2, 2016: Neurology
https://www.readbyqxmd.com/read/27913125/apomorphine-therapy-in-parkinson-s-and-future-directions
#2
Nataliya Titova, K Ray Chaudhuri
Apomorphine infusion or injection is an important dopamine agonist non-oral therapy usually used in advanced Parkinson's disease (PD) with refractory motor fluctuations. The drug also has appreciable efficacy for nonmotor fluctuations and is the quickest to reverse predictable "off" periods. Current subcutaneous administration, however, is complicated by problems associated with needle-based therapies, such as skin nodule formation, skin irritation, and avoidance of this treatment option by needle-phobic subjects...
November 30, 2016: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/27873569/establishing-a-standard-of-care-for-deep-brain-stimulation-centers-in-canada
#3
Michel Panisset, Marina Picillo, Nicolas Jodoin, Yu-Yan Poon, Alejandro Valencia-Mizrachi, Alfonso Fasano, Renato Munhoz, Christopher R Honey
During the "DBS Canada Day" symposium held in Toronto July 4-5, 2014, the scientific committee invited experts to share their knowledge regarding deep brain stimulation (DBS) management of movement disorders in three domains: (1) the programming algorithms, (2) the necessary team to run a neurosurgery program, and (3) the appropriate scales to better define in a more comprehensive fashion the effect of the brain surgery. Each presentation was followed by an open discussion, and this article reports on the conclusions of this meeting on these three questions...
November 22, 2016: Canadian Journal of Neurological Sciences. le Journal Canadien des Sciences Neurologiques
https://www.readbyqxmd.com/read/27873359/constipation-in-parkinson-s-disease-subjective-symptoms-objective-markers-and-new-perspectives
#4
REVIEW
Karoline Knudsen, Klaus Krogh, Karen Østergaard, Per Borghammer
Constipation is among the first nonmotor symptoms to develop in the prodromal phase of PD. Pathological alpha-synuclein deposition is present throughout the gastrointestinal tract up to 20 years preceding diagnosis. Nevertheless, constipation in the context of PD remains ill defined and poorly understood. In this review, we summarize current knowledge of subjective symptoms and objective measures of constipation in PD. More than 10 different definitions of constipation have been used in the PD literature, making generalizations difficult...
November 22, 2016: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/27856780/anatomo-functional-basis-of-nonmotor-symptoms-in-parkinson-disease
#5
Tadaaki Mano, Zelie Britton, Thomas Britton
No abstract text is available yet for this article.
November 16, 2016: Neurology
https://www.readbyqxmd.com/read/27855513/recent-developments-in-circulating-biomarkers-in-parkinson-s-disease-the-potential-use-of-mirnas-in-a-clinical-setting
#6
Marcia Cristina Teixeira Dos Santos, Rosie Bell, Andre Nogueira da Costa
Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting 5% of the elderly population. PD diagnosis is still based on the identification of neuromotor symptoms although nonmotor manifestations emerge years prior to diagnosis. The discovery of biomarkers at the earliest stages of PD is of extreme interest. miRNAs have been considered potential biomarkers for neurodegenerative diseases, but only a limited number have been found to be PD related. This review focuses on the current findings in the field of circulating miRNAs in PD and the challenges surrounding clinical utility and validation...
December 2016: Bioanalysis
https://www.readbyqxmd.com/read/27829983/melatoninergic-system-in-parkinson-s-disease-from-neuroprotection-to-the-management-of-motor-and-nonmotor-symptoms
#7
REVIEW
Josiel Mileno Mack, Marissa Giovanna Schamne, Tuane Bazanella Sampaio, Renata Aparecida Nedel Pértile, Pedro Augusto Carlos Magno Fernandes, Regina P Markus, Rui Daniel Prediger
Melatonin is synthesized by several tissues besides the pineal gland, and beyond its regulatory effects in light-dark cycle, melatonin is a hormone with neuroprotective, anti-inflammatory, and antioxidant properties. Melatonin acts as a free-radical scavenger, reducing reactive species and improving mitochondrial homeostasis. Melatonin also regulates the expression of neurotrophins that are involved in the survival of dopaminergic neurons and reduces α-synuclein aggregation, thus protecting the dopaminergic system against damage...
2016: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/27824807/biobehavioral-framework-of-symptom-and-health-outcomes-of-uncertainty-and-psychological-stress-in-parkinson-disease
#8
Kim W Austin, Suzanne W Ameringer, Angela R Starkweather, Leslie J Cloud, Jamie L Sturgill, Ronald K Elswick
Parkinson disease (PD) is a debilitating, progressive neurodegenerative disorder characterized by complex motor and nonmotor symptoms that fluctuate in onset, severity, level of disability, and responsiveness to treatment. The unpredictable nature of PD and the inability to halt or slow disease progression may result in uncertainty and psychological stress. Uncertainty and psychological stress have important implications for symptom and health outcomes in PD. Uncertainty and psychological stress have been shown to worsen symptoms, functional capacity, and quality of life in chronic illnesses; however, the causal mechanisms have yet to be elucidated...
December 2016: Journal of Neuroscience Nursing: Journal of the American Association of Neuroscience Nurses
https://www.readbyqxmd.com/read/27819413/the-kmds-nation-study-korean-movement-disorders-society-multicenter-assessment-of-non-motor-symptoms-and-quality-of-life-in-parkinson-s-disease-nation-study-group
#9
Do Young Kwon, Seong Beom Koh, Jae Hyeok Lee, Hee Kyung Park, Han Joon Kim, Hae Won Shin, Jinyoung Youn, Kun Woo Park, Sun Ah Choi, Sang Jin Kim, Seong Min Choi, Ji Yun Park, Beom S Jeon, Ji Young Kim, Sun Ju Chung, Chong Sik Lee, Jeong Ho Park, Tae Beom Ahn, Won Chan Kim, Hyun Sook Kim, Sang Myung Cheon, Hee Tae Kim, Jee Young Lee, Ji Sun Kim, Eun Joo Kim, Jong Min Kim, Kwang Soo Lee, Joong Seok Kim, Min Jeong Kim, Jong Sam Baik, Ki Jong Park, Hee Jin Kim, Mee Young Park, Ji Hoon Kang, Sook Kun Song, Yong Duk Kim, Ji Young Yun, Ho Won Lee, Hyung Geun Oh, Jinwhan Cho, In Uk Song, Young H Sohn, Phil Hyu Lee, Jae Woo Kim
BACKGROUND AND PURPOSE: Nonmotor symptoms (NMS) in Parkinson's disease (PD) have multisystem origins with heterogeneous manifestations that develop throughout the course of PD. NMS are increasingly recognized as having a significant impact on the health-related quality of life (HrQoL). We aimed to determine the NMS presentation according to PD status, and the associations of NMS with other clinical variables and the HrQoL of Korean PD patients. METHODS: We surveyed patients in 37 movement-disorders clinics throughout Korea...
October 2016: Journal of Clinical Neurology
https://www.readbyqxmd.com/read/27800210/classification-and-characteristics-of-pain-associated-with-parkinson-s-disease
#10
REVIEW
Marcelo Rezende Young Blood, Marcelo Machado Ferro, Renato Puppi Munhoz, Hélio Afonso Ghizoni Teive, Carlos Henrique Ferreira Camargo
Neuropsychiatric symptoms and pain are among the most common nonmotor symptoms of Parkinson's disease (PD). The correlation between pain and PD has been recognized since its classic descriptions. Pain occurs in about 60% of PD patients, two to three times more frequent in this population than in age matched healthy individuals. It is an early and potentially disabling symptom that can precede motor symptoms by several years. The lower back and lower extremities are the most commonly affected areas. The most used classification for pain in PD defines musculoskeletal, dystonic, central, or neuropathic/radicular forms...
2016: Parkinson's Disease
https://www.readbyqxmd.com/read/27800022/evidence-for-the-use-of-pimavanserin-in-the-treatment-of-parkinson-s-disease-psychosis
#11
REVIEW
Harini Sarva, Claire Henchcliffe
Parkinson's disease (PD) is a progressive neurodegenerative disorder with both motor and nonmotor symptoms (NMS), leading to significant morbidity and caregiver burden. Psychosis is common but is under recognized by physicians. When present, it increases the patient's risk of hospitalization and nursing home placement and caregiver burden. Although the atypical antipsychotic agent, clozapine, has been considered the gold standard treatment, severe agranulocytosis in 0.38% of patients and more commonly milder leukopenia, resulting in frequent blood testing, limit its use...
November 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27786242/advances-in-markers-of-prodromal-parkinson-disease
#12
REVIEW
Ronald B Postuma, Daniela Berg
Efforts to develop neuroprotective therapy for Parkinson disease (PD) are focusing on the early stages of disease, which offer the best opportunity to intervene. Early PD can be divided into preclinical, prodromal and clinical stages; in this Review, we focus on the prodromal stage and markers that can be used to identify prodromal PD. We consider the necessary properties of a marker, before providing an overview of the proven and potential markers of prodromal PD, including clinical nonmotor markers, clinical motor markers, neuroimaging markers and tissue biomarkers...
October 27, 2016: Nature Reviews. Neurology
https://www.readbyqxmd.com/read/27784075/visual-contrast-sensitivity-in-early-stage-parkinson-s-disease
#13
Wendy Ming, Dimitrios J Palidis, Miriam Spering, Martin J McKeown
Purpose: Visual impairments are frequent in Parkinson's disease (PD) and impact normal functioning in daily activities. Visual contrast sensitivity is a powerful nonmotor sign for discriminating PD patients from controls. However, it is usually assessed with static visual stimuli. Here we examined the interaction between perception and eye movements in static and dynamic contrast sensitivity tasks in a cohort of mildly impaired, early-stage PD patients. Methods: Patients (n = 13) and healthy age-matched controls (n = 12) viewed stimuli of various spatial frequencies (0-8 cyc/deg) and speeds (0°/s, 10°/s, 30°/s) on a computer monitor...
October 1, 2016: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/27781138/depressive-symptoms-associated-with-concerns-about-falling-in%C3%A2-parkinson-s-disease
#14
Erika Franzén, David Conradsson, Maria Hagströmer, Maria H Nilsson
BACKGROUND: Concerns about falling, a construct related to fear of falling, is increased in people with Parkinson's disease (PD) and is recognized as a barrier for exercise, negatively affecting health-related quality of life and participation. AIM: To investigate modifiable factors associated with concerns about falling in elderly with mild-to-moderate PD. METHODS: Eighty-nine elderly (39 females, mean age 73 years) with mild-to-moderate PD were recruited...
October 2016: Brain and Behavior
https://www.readbyqxmd.com/read/27772789/neuropsychiatric-characteristics-of-gba-associated-parkinson-disease
#15
Matthew Swan, Nancy Doan, Robert A Ortega, Matthew Barrett, William Nichols, Laurie Ozelius, Jeannie Soto-Valencia, Sarah Boschung, Andres Deik, Harini Sarva, Jose Cabassa, Brooke Johannes, Deborah Raymond, Karen Marder, Nir Giladi, Joan Miravite, William Severt, Rivka Sachdev, Vicki Shanker, Susan Bressman, Rachel Saunders-Pullman
Mutations in GBA1 are a well-established risk factor for Parkinson disease (PD). GBA-associated PD (GBA-PD) may have a higher burden of nonmotor symptoms than idiopathic PD (IPD). We sought to characterize the relationship between GBA-PD and neuropsychiatric symptoms. Subjects were screened for common GBA1 mutations. GBA-PD (n=31) and non-carrier (IPD; n=55) scores were compared on the Unified Parkinson Disease Rating Scale (UPDRS), Montreal Cognitive Assessment (MoCA), Beck Depression Inventory (BDI), and the State-Trait Anxiety Index (STAI)...
November 15, 2016: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/27757037/pain-management-in-patients-with-parkinson-s-disease-challenges-and-solutions
#16
Orjan Skogar, Johan Lokk
This review focuses on the diagnosis and management of Parkinson-related pain which is one of the more frequently reported nonmotor symptoms in Parkinson's disease (PD), which is the second most common neurodegenerative disease after Alzheimer's disease. Pain is ranked high by patients as a troublesome symptom in all stages of the disease. In early-stage PD, pain is rated as the most bothersome symptom. Knowledge of the correct diagnosis of pain origin and possible methods of treatments for pain relief in PD is of great importance...
2016: Journal of Multidisciplinary Healthcare
https://www.readbyqxmd.com/read/27749396/clinical-subtypes-and-genetic-heterogeneity-of-lumping-and-splitting-in-parkinson-disease
#17
Rainer von Coelln, Lisa M Shulman
PURPOSE OF REVIEW: Recent studies on clinical, genetic and pathological heterogeneity of Parkinson disease have renewed the old debate whether we should think of Parkinson disease as one disease with variations, or as a group of independent diseases that happen to present with similar phenotypes. Here, we provide an overview of where the debate is coming from, and how recent findings in clinical subtyping, genetics and clinico-pathological correlation have shaped this controversy over the last few years...
December 2016: Current Opinion in Neurology
https://www.readbyqxmd.com/read/27748239/reduced-rapid-eye-movement-density-in-parkinson-disease-a-polysomnography-based-case-control-study
#18
Lynn A Schroeder, Olivier Rufra, Nicolas Sauvageot, François Fays, Vannina Pieri, Nico J Diederich
STUDY OBJECTIVES: To explore rapid eye movement density (RD) in patients with idiopathic Parkinson disease (IPD) and to investigate its usefulness as surrogate marker of excessive daytime sleepiness, a frequent complaint in IPD patients. METHODS: Retrospective polysomnography study on 81 subjects without dementia: 29 patients with early-stage IPD (disease duration >3 y), 21 patients with middle- stage IPD (disease duration >3 and <8 y) and 31 healthy controls (HC)...
October 10, 2016: Sleep
https://www.readbyqxmd.com/read/27741433/mulberry-fruit-ameliorates-parkinson-s-disease-related-pathology-by-reducing-%C3%AE-synuclein-and-ubiquitin-levels-in-a-1-methyl-4-phenyl-1-2-3-6-tetrahydropyridine-probenecid-model
#19
Pil Sung Gu, Minho Moon, Jin Gyu Choi, Myung Sook Oh
Mulberry fruit, which has been long used in traditional oriental medicine, was reported to ameliorate motor dysfunction and dopaminergic neuronal degeneration via antioxidant and antiapoptotic effects in an animal model of Parkinson's disease (PD). More than 95% of PD patients exhibit nonmotor problems such as olfactory dysfunction and gastrointestinal constipation, which are generally considered to be early symptoms of PD. However, few studies have actually examined potential drugs to treat early PD symptoms...
January 2017: Journal of Nutritional Biochemistry
https://www.readbyqxmd.com/read/27730767/cardiovascular-autonomic-dysfunction-in-patients-with-drug-induced-parkinsonism
#20
Joong Seok Kim, Dong Woo Ryu, Ju Hee Oh, Yang Hyun Lee, Sung Jin Park, Kipyung Jeon, Jong Yun Lee, Seong Hee Ho, Jungmin So, Jin Hee Im, Kwang Soo Lee
BACKGROUND AND PURPOSE: Recent studies have shown that several nonmotor symptoms differ between Parkinson's disease (PD) and drug-induced parkinsonism (DIP). However, there have been no reports on cardiovascular autonomic function in DIP, and so this study investigated whether cardiovascular autonomic function differs between PD and DIP patients. METHODS: This study consecutively enrolled 20 DIP patients, 99 drug-naïve PD patients, and 25 age-matched healthy controls who underwent head-up tilt-table testing and 24-h ambulatory blood pressure monitoring...
October 7, 2016: Journal of Clinical Neurology
keyword
keyword
70016
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"